| 1 |
<p><b>Research & Development at PLIVA</b></p> |
<p align="center"><b>RESEARCH AND DEVELOPMENT</b></p> |
| 2 |
<p><b>Vision</b></p> |
<p>PLIVA has a long and successful R&D track record that dates back to 1936. Its |
| 3 |
<ul> |
investments in R&D have grown to a decade high of USD 40 m and represent 10% |
| 4 |
<li>To become a leading company in anti-infective research</li> |
of PLIVA's healthcare turnover. This strategic goal for this continued investment |
| 5 |
<li>To become an internationally recognized center for inflammation research</li> |
is to achieve a balanced portfolio for PLIVA's short, medium and long-term growth. |
| 6 |
<li>To generate NMEs with the objective of producing commercial returns in line |
Commitment to a unique two-fold R&D strategy: discovery and development of novel |
| 7 |
with the PLIVA's growth targets</li> |
chemical entities and development of value added generics, is further supported |
| 8 |
<li>To develop novel drugs which will serve as yet unmet medical needs at launch</li> |
by PLIVA's licensing strategy.</p> |
| 9 |
</ul> |
<p>PLIVA has focused its research expertise in two therapeutic areas: anti-infectives |
| 10 |
|
and anti-inflammatories, and through this "Smart Discovery Strategy" globally |
| 11 |
|
competitive results are expected. Research activities are focussing on the early |
| 12 |
|
phases of discovery and development only, while for advanced stages of development |
| 13 |
|
and marketing, strategic partnerships will be established. PLIVA's vision in |
| 14 |
|
research is to develop new drugs whose production will serve unmet medical needs |
| 15 |
|
and will have commercial returns in line with PLIVA's growth targets. At present, |
| 16 |
|
there are three potential new drugs in PLIVA's pipeline.</p> |
| 17 |
<p align="center"><img src="p/Superrnd_ljudi_4.jpg" width="300" height="198"></p> |
<p align="center"><img src="p/Superrnd_ljudi_4.jpg" width="300" height="198"></p> |
| 18 |
<p><b>Strategy</b></p> |
<p>In development, superior results will be achieved by the in-house development |
| 19 |
<p>Within the last five years, PLIVA has been undergoing a vigorous process of |
of new molecules, the development of final pharmaceutical Rx or OTC drug forms, |
| 20 |
change to reshape its R&D operations in order to meet international standards |
and the development of Fine Chemicals processes. PLIVA's Competitive Generic |
| 21 |
and future global challenges. PLIVA sees its continued R&D success as being |
Strategy is based on decades of experience and expertise in new API development |
| 22 |
based on the combination of its international research team in Zagreb, a network |
coupled with regular and successful FDA inspections as well as PLIVA's excellence |
| 23 |
of strategic partnerships with multinational and biotech companies, and broad |
in chemistry and the innovative improvement of existing drugs.</p> |
| 24 |
co-operation with various international universities and institutes. In addition, |
<p>Our R&D strategy binds together a top quality international research team, |
| 25 |
PLIVA's R&D locations at PLIVA Lachema (Brno, the Czech Republic) and PLIVA |
a network of strategic partnerships with multinational and biotech companies |
| 26 |
Krakow (Krakow, Poland) give it unique access to experience and skills, particularly |
and a broad cooperation with various international universities and institutes. |
| 27 |
in the development of NCEs and generics. Furthermore, local presence on the |
These activities are further supported by an independent body that consists |
| 28 |
developing markets of Central and Eastern Europe will give PLIVA a competitive |
of leading experts in the R&D areas of interest to PLIVA - PLIVA's International |
| 29 |
advantage in the development and registration of its products.</p> |
Scientific Advisory Board.</p> |
| 30 |
<p>At its main research location in Zagreb, PLIVA maintains all the necessary |
<p>During the year 2000, 5 new patent applications were submitted in Croatia: |
| 31 |
technology for synthetic chemistry, structure based drug design, molecular biology, |
TNF-a Inhibitors, New Coumarins, and Torasemide polymorphs; 6 new patent applications |
| 32 |
pharmacology, toxicology, process development and pharmaceutical technology. |
were submitted in the UK, resulting from the PLIVA-GlaxoWellcome joint macrolide |
| 33 |
This enables accurate evaluation of compounds and research proposals at early |
project; 8 patents from the year 2000 and the previous year were also submitted |
| 34 |
stages and allows more rapid movement toward clinical development. In general, |
abroad as PCTs: Macrolides and Torasemide polymorphs. As well, PLIVA researchers |
| 35 |
PLIVA is looking to bring projects from the Discovery stage to Phase II clinical |
and scientists continue to publish and lecture in the professional media. </p> |
|
trials, thereafter seeking a partner for global development and marketing.</p> |
|
Parent Directory
| 
Revision Log
| 
Patch